OBJECTIVES: Diabetes Mellitus II (DM type II) is characterized by high prevalence and severe vascular complications. They are the main cause of disability and death in DM patients and lead to grave social and economic consequences. The objective of the present study was to assess the impact of selective inhibitors of sodium-glucose co-conveyor type 2 on frequency of complications and the costs per QALY comparing with inhibitors dipeptidyl peptidase-4 type.  METHODS: Modeling using Global «Cardiff diabetes model» in time horizon of 25 years. Strategy I: Line I - selective inhibitors of sodium-glucose co-conveyor type 2 (for example, dapagliflozin), Line II - Line I + metformin; Line III: insulin. Strategy II: Line I - inhibitors dipeptidyl peptidase-4 type (for example, sitagliptin); Line II - Line I + metformin; Line III: insulin. The direct medical costs of medicines, out -patients care and fatal complications were evaluated and cost utility analysis (CUA) were held.  RESULTS: The direct medical costs for Strategy I for 1000 patients during 25 years were 5 309 305 USD: for Strategy II - 5 316 676 USD (7 371 USD higher). The strategy I helps to prevent the 11 fatal complications among 1000 DM type II patients. Reducing the frequency of complications provide saving 22 523 USD for cohort during 25 years. Costs per QALY for Strategy I were on 26 UDS less than for Strategy II. The results of CUA were proved by sensitivity analysis. CONCLUSIONS: Present study has shown that selective inhibitors of sodium-glucose co-conveyor type 2 is more cost-effective as a first line therapy thanks to reducing the frequency of fatal vascular complications and the costs per QALY.